hexahydro-cyclopentaimidazol-2-one | 5587-80-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: hexahydro-cyclopentaimidazol-2-one
• 英文别名: 1,2-Ureylen-cyclopentan；hexahydrocyclopenta[d]imidazol-2(1H)-one；3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[d]imidazol-2-one
• CAS: 5587-80-4
• 化学式: C₆H₁₀N₂O
• 分子量: 126.158
• InChiKey: QJDLOPZFRBHNDM-UHFFFAOYSA-N

物化性质

• 沸点：
  364.1±11.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  hexahydro-cyclopentaimidazol-2-one 生成 (1S,2R)-1-N,1-N,2-N,2-N-四甲基环戊烷-1,2-二胺
  参考文献：
  名称：

  Efficient one-step synthesis of a cis vicinal tertiary diamine and its complexation to a lithium carbanion salt

  摘要：

  DOI：

  10.1021/jo00181a047
• 作为产物：
  描述：

  7-oxo-6-aza-bicyclo[3.2.0]heptane-6-sulfonyl chloride 在 triethylammonium azide 作用下， 生成 hexahydro-cyclopentaimidazol-2-one
  参考文献：
  名称：

  Efficient one-step synthesis of a cis vicinal tertiary diamine and its complexation to a lithium carbanion salt

  摘要：

  DOI：

  10.1021/jo00181a047

文献信息

• [EN] ARYLETHYNYL DERIVATIVES<br/>[FR] DÉRIVÉS D'ARYLÉTHYNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011128279A1

  公开（公告）日：2011-10-20

  The present invention relates to ethynyl derivatives of formula (I) as allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). The variables in formula (I) are defined in the specification.

  本发明涉及式(I)的乙炔衍生物，作为代谢型谷氨酸受体亚型5（mGluR5）的别构调节剂。式(I)中的变量在说明书中有定义。
• Bicycle pyrazole derivative
  申请人：Nakahira Hiroyuki

  公开号：US20070082908A1

  公开（公告）日：2007-04-12

  A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R 1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A 1 and A 2 indicate a double bond (A 1 =A 2 ), etc.; A 1 represents a group represented by the formula C(R 2 ), etc.; A 2 represents a group represented by the formula C(R 4 ), etc.; R 2 represents hydrogen, optionally substituted alkyl, etc.; R 4 represents hydrogen, optionally substituted alkyl, etc.; R 6 represents hydrogen, optionally substituted aryl, etc.; and —Y represents, e.g.; a group represented by the formula (A): (A) (wherein m1 is 0, 1, 2, or 3; and R 7 is absent, or one or two R 7 's are present and each independently represents optionally substituted alkyl, etc.).]

  以下化合物的公式（I）或其前药，或者是任何一种药学上可接受的盐。这些化合物具有高DPP-IV抑制活性和改善安全、无毒性等特点。（I）[在公式中，R1代表氢，可选取代的烷基等；A1和A2之间的实线和虚线表示双键（A1=A2），等等；A1代表由公式C（R2）等表示的基团；A2代表由公式C（R4）等表示的基团；R2代表氢，可选取代的烷基等；R4代表氢，可选取代的烷基等；R6代表氢，可选取代的芳基等；而—Y代表例如由公式（A）表示的一个基团：（A）（其中m1为0、1、2或3；R7不存在，或者存在一个或两个R7，每个独立地代表可选取代的烷基等）。]
• 2,4-Diazabicyclo(3.3.0)octane-3-one derivatives, their preparation and their pharmaceutical formulation
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0046597B1

  公开（公告）日：1985-07-03
• ARYLETHYNYL DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2558457A1

  公开（公告）日：2013-02-20
• CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：BioMarin Pharmaceutical Inc.

  公开号：US20190134005A1

  公开（公告）日：2019-05-09

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.